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Abstract
Introduction During the menstrual cycle, the mammary gland
goes through sequential waves of proliferation and apoptosis. In
mammary epithelial cells, hormonal and non-hormonal factors
regulate apoptosis. To determine the cyclical effects of gonadal
steroids on breast homeostasis, we evaluated the apoptotic
index (AI) determined by terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) staining in human
mammary epithelial cells during the spontaneous menstrual
cycle and correlated it with cellular proliferation as determined
by the expression of Ki-67 during the same period.
Methods Normal breast tissue samples were obtained from 42
randomly selected patients in the proliferative (n = 21) and luteal
(n = 21) phases. Menstrual cycle phase characterization was
based on the date of the last and subsequent menses, and on
progesterone serum levels obtained at the time of biopsy.
Results The proliferation index (PI), defined as the number of Ki-
67-positive nuclei per 1,000 epithelial cells, was significantly
larger in the luteal phase (30.46) than in the follicular phase
(13.45; P = 0.0033). The AI was defined as the number of
TUNEL-positive cells per 1,000 epithelial cells. The average AI
values in both phases of the menstrual cycle were not
statistically significant (P = 0.21). However, the cell renewal
index (CRI = PI/AI) was significantly higher in the luteal phase (P
= 0.033). A significant cyclical variation of PI, AI and CRI was
observed. PI and AI peaks occurred on about the 24th day of the
menstrual cycle, whereas the CRI reached higher values on the
28th day.
Conclusions We conclude that proliferative activity is
dependent mainly on hormonal fluctuations, whereas apoptotic
activity is probably regulated by hormonal and non-hormonal
factors.
Keywords: apoptosis, Ki-67, mammary gland, menstrual cycle, TdT-mediated dUTP nick end labeling
Introduction
The cyclical transformations and cellular kinetics of the
mammary gland have long been the subject of intense
investigation. Interest in alterations caused by steroid
actions, specifically on epithelial proliferation, has risen
sharply in the past decade owing to increasing numbers of
breast carcinomas in the female population [1]. There is
also an immediate need for more accurate predictors of
breast cancer risk, particularly in light of the various chem-
oprevention trials under way.
Understanding the factors and mechanisms that regulate
hormone-related changes in the normal human breast is
crucial, because alterations in breast structure and function
during the menstrual cycle could predispose this tissue to
malignant changes and hence to the development of breast
cancer. The present study focuses on epithelial cells, the
primary target for carcinogenesis, as demonstrated by var-
ious histological studies indicating that most breast tumors
arise in the epithelial cell population [2].R306
AI = apoptotic index; CRI = cell renewal index; EGFR = epidermal growth factor receptor; ER = estrogen receptor; PBS = phosphate-buffered saline; 
PI = proliferation index; TdT = terminal deoxynucleotidyl transferase; TUNEL = TdT-mediated dUTP nick end labeling.
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activity of epithelial cells in the normal breast throughout
the menstrual cycle [3-8], an underlying limitation in these
studies is the concurrent use of oral contraceptives by
many of the patients studied. In addition, studies with the
thymidine labeling index demonstrated that proliferative
activity declines with age [7,8], thus requiring standardiza-
tion of the data to reduce variability. Finally, these studies
do not provide a clear explanation for the hormone-related
variations in programmed cell death (apoptosis) and mito-
sis (proliferation) observed during the menstrual cycle.
It is well known that the mammary gland undergoes mor-
phological modifications during the menstrual cycle. Epi-
thelial proliferation is greatest during the luteal phase,
suggesting a synergistic influence of estrogen and proges-
terone [9,10]. Work by Ferguson and Anderson [5] and by
Anderson and colleagues [6], using a linear regression
model, suggests that there are cyclical variations in epithe-
lial apoptosis levels, with maximal apoptotic expression on
the 28th day of the menstrual cycle, approximately 3 days
after the mitotic peak. This coincides with decreasing levels
of estrogen and progesterone at the end of the menstrual
cycle. Although small temporal differences were found
between the two phenomena, the authors stated that it was
not possible to assume a link between mitosis and apopto-
sis in those studies. Because the number of cells undergo-
ing cell death was very low, apoptotic frequency was
evaluated per mammary lobule (approximately 50 lobules
per case). The few apoptotic cells observed seemed to be
randomly distributed in the lobule, within central and
peripheral ducts. The authors also included patients in
whom neither apoptosis nor mitosis could be observed,
requiring mathematical manipulation of the data obtained in
all cases examined in order to derive mitotic and apoptotic
frequencies. Indeed, in the study by Anderson and col-
leagues [6], it is still unclear whether the apoptotic activity
described was more intense at the end of the luteal phase
because it followed increased mitotic activity in the days
before or because it was independently greater during that
period of the menstrual cycle.
To clarify the cyclical effects of gonadal steroids on breast
homeostasis, we evaluated the apoptotic index (AI) in
human mammary epithelial cells (by terminal deoxynucleoti-
dyl transferase-mediated dUTP nick end labeling (TUNEL)
staining [11]) during the spontaneous (natural) menstrual
cycle and correlated it with cellular proliferation as deter-
mined by Ki-67 expression [12] during the same period.
We also correlated the progesterone levels with apoptosis
and proliferation irrespective of the stage of the cycle.
Materials and methods
Patients
The series consisted of 42 patients (age 21.8 ± 6.1 years
(mean ± standard deviation), range 14 to 38 years) under-
going excision of fibroadenomas, a condition thought not
be associated with an increased risk of cancer, at the
Department of Gyneology, Mastology Division, Federal Uni-
versity of São Paulo, Paulista Medical School. Institutional
review board approval was obtained and patients signed
an informed consent before enrollment in the study. Inclu-
sion criteria for entry into the study were as follows: female
sex, regular menstrual cycles (intervals of 28 ± 2 days) in
the previous 6 months, and with a known date of last men-
strual period. Exclusion criteria were: use of hormone ther-
apy in the previous 12 months, pregnancy, females nursing
in the previous 12 months, patients with any type of endo-
crine pathology, or patients taking any type of medication at
the time that tissue for the study was obtained.
Patients underwent a complete medical exam, ultrasonog-
raphy, and fine needle aspiration with subsequent micro-
scopic analysis to confirm that the mammary lesion was
benign. All patients were randomized into two groups
according to the phase of their menstrual cycle, which was
determined by the date of the patient's previous as well as
subsequent menstrual period: group A, follicular phase
(age 23.5 ± 6.6 years (mean ± SD)); group B, luteal phase
(age 20.0 ± 5.2 years). Progesterone levels were examined
by radioimmunoassays, with values of 3.0 ng/ml or more
considered compatible with adequate luteal activity [13].
The mammary tissue was obtained with a local anesthetic
without vasoconstrictors (2% lidocaine was used), at about
1:00 pm to minimize the effects of circadian rhythms on
hormone release [4,14] and on cellular kinetics [15,16].
The parenchymal mammary tissue removed (at least 1 cm
from the lesion) was without any gross microscopic altera-
tions [17].
Histopathology, TUNEL and immunohistochemistry
After fixation in 10% formaldehyde and embedding in par-
affin, tissues samples were cut into 4 µm sections, depar-
affinized in xylene and hydrated in a series of ethanol
washes, stained with hematoxylin and eosin, and examined
for any pathological abnormalities. TUNEL staining was
performed with the ApopTag Plus in situ Apoptosis Detec-
tion Kit (Oncor, Gaithersburg, MD, USA). Tissue sections
were deparaffinized and hydrated as above, and stripped of
proteins by incubation with 20 µg/ml proteinase K (42°C)
for 15 min. The slices were then washed in distilled water
and PBS and incubated in 3% H2O2 to remove endog-
enous peroxidases. After equilibration, the sections were
incubated at 37°C in terminal deoxynucleotidyl transferase
(TdT) enzyme and digoxigenin-labeled substrate for 1 hour.
Antidigoxigenin was then applied, and detection was
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The sections were then counterstained with methyl green,
cleared, and mounted. Sections treated with DNAse I
enzyme were used as positive controls (Amersham, Cleve-
land, OH, USA), and sections from which TdT enzyme was
omitted were used as negative controls. Adjacent sections
were used for Ki-67 immunohistochemical staining. Sec-
tions were deparaffinized, hydrated, incubated with protei-
nase K, washed in distilled water and PBS, and incubated
with 3% H2O2 as above. Blocking serum was applied for
20 min and sections were then sequentially incubated in
primary mouse anti-human Ki-67 antibody (1:100, clone Ki-
S5; Dako, Carpinteria, CA, USA) for 1 hour, biotinylated
rabbit anti-mouse IgG (Dako LSAB kit) for 12 min, and
ABC reagent (avidin and biotinylated horseradish peroxi-
dase complex) for 30 min (ABC kit; Vector, Burlingame,
CA, USA). Detection was accomplished with diaminoben-
zidine substrate solution until the desired staining intensity
was obtained (3 to 5 min). The sections were then counter-
stained with hematoxylin and eosin, cleared, and mounted.
Quantitative evaluation of Ki-67 expression and TUNEL
positivity was performed in epithelial cells from the anatom-
ically normal mammary gland (without any fibrocystic
changes), including central and peripheral ducts within the
lobules; myoepithelial and lymphoid cells were excluded.
Cells were counted as apoptotic only if they were TUNEL-
positive and showed characteristic nuclear morphology
typical of apoptosis (that is, cells containing pyknotic nuclei
plus apoptotic bodies). Successive counts, performed by
individuals blinded to the groups, were made until 1,000
cells per tissue sample had been examined. Two indices
were thus obtained: the proliferation index (PI), defined as
the number of Ki-67-positive nuclei per 1,000 epithelial
cells, and the AI, defined as the number of TUNEL-positive
cells per 1,000 epithelial cells counted. From these values
the cell renewal index (CRI = PI/AI) was obtained.
Statistical analysis
Statistical analyses were performed with analysis of vari-
ance for continuous data followed by Student's t-test, and
with non-parametric tests (Mann–Whitney U test) for non-
continuous data (gestation and parity). Fisher's exact test
was used to verify the homogeneity of the samples relative
to nursing history. The variation in frequency of proliferation
and apoptosis relative to variations in the menstrual cycle
as well as the variation in frequency of proliferation and
apoptosis relative to the progesterone levels were meas-
ured with linear regression models and fourth-degree poly-
nomial curves (Polnom Program; University of Manchester,
Manchester, UK) as indicated. All data are expressed as
means ± SD; P < 0.05 was considered significant.
Results
There were no differences between patients in group A (fol-
licular phase) and group B (luteal phase) in terms of age of
menstruation onset (12.8 ± 1.3 and 12.7 ± 1.4, respec-
tively), number of pregnancies, parity, and lactation history.
The mean PI for group A was 13.5 ± 9.8, significantly
smaller than in group B, which had a PI of 30.5 ± 22 (P =
0.003, by Student's t-test). Photomicrographs from repre-
sentative patients showing Ki-67 expression for both
groups are shown in Fig. 1a,b. The AI for both groups was
very similar: group A (4.4 ± 1.8) and group B (5.2 ± 2.4; P
= 0.21). TUNEL-positive cells from representative patients
for each group are given in Fig. 1C–E; Fig. 1f shows a
highly magnified TUNEL-positive cell displaying the charac-
teristic features of chromatin condensation and apoptotic
bodies. The CRI for group A (3.8 ± 3.4) was also signifi-
cantly smaller than that for group B (7.4 ± 6.6; P = 0.03).
The data show that, in a 28-day interval, the number of pro-
liferative, apoptotic, and cell renewal events vary as a func-
tion of time. The linear regressions for each one of the
indices are shown in Fig. 2a,c,e. The cyclical variability
shows that the highest proliferation values occur near the
end of the menstrual cycle, whereas the AI is greatest at the
beginning and the end of the menstrual cycle. The CRI
shows cyclical variations, with significantly greater values
near the 28th day of the menstrual cycle (P = 0.033). The
fourth-degree polynomial curves show that neither the PI (P
= 0.6; Fig. 2b) nor the CRI (P = 0.25; Fig. 2f) is statistically
different throughout the course of the menstrual cycle. In
contrast, there is a statistically significant cyclical variability
in the AI (P = 0.038; Fig. 2d). The mathematical equations
that best represent the PI and AI are the linear regression
and the fourth-degree polynomial curve, respectively.
When these are superimposed, after mathematical adjust-
ment of the median visible time of Ki-67 expression with
that of apoptosis, it is clear that the maximum values for
both indices (PI and AI) coincide at about the 24th day of
the menstrual cycle. At this point, the linear regression for
the PI is tangential to the fourth-degree polynomial (Fig.
2g).
Furthermore, progesterone levels, irrespective of the stage
of the cycle, correlate with proliferation. In apoptosis this is
not so, because we found a decrease in apoptosis at pro-
gesterone levels higher than 15 ng/ml (Fig. 2h).
It is important to note that, relative to the total number of
cells present, the number of epithelial cells undergoing pro-
liferation or apoptosis at any given time during the men-
strual cycle was quite small, and the cells were distributed
throughout the mammary lobules.
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The mammary gland undergoes cyclical changes in
response to the hormonal fluctuations of the menstrual
cycle. The epithelium responds to these systemic hormonal
changes by regional proliferation, differentiation, and pro-
grammed cell death, also known as apoptosis [18]. In the
present study of normal mammary tissue we observed that
this epithelial response is limited to a small fraction of the
cells, suggesting that there is probably local regulation of
cell survival and death in this tissue. Similar results were
obtained by Andres and Strange [18], who also noted that
cells undergoing proliferation or apoptosis were isolated,
distributed in various mammary lobules, and positioned
close to the lumen.
Proliferation and apoptosis in normal breast tissue are influ-
enced by several factors, including phase of the menstrual
cycle, chronological age, breast age, use of oral contracep-
tives (especially if nulliparous) and recent parity [19]. It is
therefore imperative to use strict criteria when selecting
patients for studies of normal mammary tissue. Several pre-
vious studies have examined cell turnover in morphologi-
cally normal human mammary gland epithelium [4-8,16,20-
22]. However, interpretation of the results of these studies
is difficult for four reasons: first, the menstrual and parity
status of the groups were not reported [23]; second, the
studies included patients of perimenopausal and/or meno-
pausal age [5,8,23-25]; third, several of the patients stud-
ied were using oral contraceptives [5,8,24,26]; and fourth,
there are no available data about, or there was no assess-
ment of, the phase of the menstrual cycle with progester-
one levels [5,8,23,24,26]. In the present study, all of the
above parameters were evaluated and/or controlled for.
As reviewed by Brown and Gatter [27], the PI of any tissue
is determined by the growth fraction, which can be
assessed by Ki-67 expression, and the time it takes the cell
to complete the cell cycle. Thus, tissues in which many
cells are in a very long cycle show extensive Ki-67 expres-
sion but not a very large PI. In contrast, tissues in which a
few cells are in a very short cycle have a higher PI but few
Ki-67-positive cells. Because Ki-67 is expressed through-
out the cell cycle (G1, S, G2 and M phase), is quickly
degraded and is not found in cells undergoing DNA repair
[12], its expression provides information only about
whether a cell is in the cycle, but not about the cycle length.
In accordance with previous studies [5,20], we find that the
PI (the number of Ki-67-positive nuclei per 1,000 epithelial
cells) of the human mammary epithelium is significantly
greater in the luteal phase of the menstrual cycle, both
Figure 1
Photomicrographs of human mammary tissue during the follicular and luteal phases of the natural menstrual cycle. (a,b) Ki-67 expression (arrows 
and/or deep brown color) in epithelial cells from normal mammary lobule of a representative patient in the follicular phase (a) and in the luteal phase 
(b). (c–f) TdT-mediated dUTP nick end labelling (TUNEL)-positive staining (arrows, deep brown color) indicating apoptotic epithelial cells from rep-
resentative patients in the follicular phase (c,d) and in the luteal phase (e,f); (f) high magnification of a labeled cell displaying the characteristic fea-
tures of chromatin condensation and apoptotic bodies.
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measured by linear regression.
The mechanisms by which steroid hormones stimulate
mammary epithelium growth are controversial and continue
to be the source of intense investigation. Various studies
suggest that the regulation of cell proliferation occurs via
three main mechanisms, namely receptor-mediated [28-
36], an autocrine/paracrine loop [37], and negative feed-
back [38,39]. Among the specific hormone receptors
involved, two estrogen receptors (ERs) are of particular
interest: ER-α, the predominant subtype in the mammary
gland, and ER-β [40]. In normal mammary tissue, the frac-
tion of epithelial cells that express ER is small [41]. Recent
studies have shown that the ER is a ligand-dependent tran-
scription factor, which accounts for the latency of most
estrogenic responses in target tissues [42]. The ER can
regulate gene transcription either directly or indirectly and,
depending on the patterns of co-regulator recruitment to
the ligand–receptor–gene assembly, can elicit either the
stimulation or inhibition of specific biological effects [43].
Additionally, binding of estrogen to the ER can be modu-
Figure 2
Linear regressions and polynomial curves for the proliferation index (a,b), apoptotic index (c,d) and cell renewal index (e,f) r lif r ti  i  ( , ), a t tic index (c,d) and cel  renewal index (e,f). The graphs that best rep-
resent the proliferation and the apoptotic indexes were the linear regression (a,c,e) and the polynomial curve (b,d,f), respectively. (g) By superimpos-
ing the data after mathematically adjusting the mean visible time of Ki-67 expression [53] with that of the apoptotic index, one confirms that the 
maximum values for both indices coincide at about day 24 of the menstrual cycle (the point at which the linear regression and polynomial curves are 
tangential). (h) Correlation of progesterone levels with apoptosis and proliferation irrespective of the stage of the menstrual cycle.
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progesterone receptor, progesterone is the physiological
negative regulator of estrogen activation [45].
It is possible that steroid hormone fluctuations influence the
activation of gene transcription in target mammary cells.
These target cells express different types and levels of reg-
ulatory proteins in the first and second phases of the men-
strual cycle. They require a latency period to initiate the
transcription of regulatory factors that activate the cell
cycle, culminating with greater proliferation in the second
phase of the menstrual cycle.
In the breast, proliferation and apoptosis of the mammary
epithelium occur in response to estrogen and other hor-
mones. One of the classical examples of apoptosis is the
involution of the post-lactating mammary gland, in which
the loss of lactogenic hormones results in collapse of the
gland due, in large part, to a programmed elimination of dif-
ferentiated mammary epithelial cells [46]. In the present
study we observe that the apoptotic activity does not vary
significantly between the luteal and follicular phases. More-
over, our results show that apoptosis reaches maximum val-
ues in the middle of the luteal phase (at about day 24 of the
menstrual cycle), but there is also a small elevation in
TUNEL-positive nuclei at about the third day of the cycle.
This is in contrast to the study by Ferguson and Anderson
[5], who found significant cyclical variations in the apop-
totic frequency. The reason for the discrepancy in results is
unclear but could be related to differences in methodology
and patient selection criteria. It is also important to note that
in the study by Ferguson and Anderson [5] the significance
in cyclical variations is only evident in the logarithm of the
transformed, or mathematically adjusted, values for the
mitotic and apoptotic frequencies against day of the men-
strual cycle. In the present study there is no need to trans-
form any of the values obtained, and we find that the curve
that best fits the results is the fourth-degree polynomial.
It is also likely that cyclical variations take place in the rate
with which mitotic and apoptotic events occur, thus affect-
ing the time periods at which these phenomena are visible
[47]. The outliers in the data may be related to this
phenomenon.
The number of events and the rate at which they occur have
not been concomitantly evaluated. It is therefore possible
that the increase in events during the luteal phase of the
menstrual cycle is simply due to the fact that these events
are visible for longer during that phase, and not because
the absolute number of events is greater at that time relative
to the follicular phase. Finally, the increase in events in the
luteal phase may be due to a combination of an increased
visible time and an increased number of events. Further
studies with multi-parameter analysis, allowing us to differ-
entiate between event numbers, duration, and rate of
appearance, are needed to understand the cyclical effects
of gonadal steroids on breast homeostasis.
Mammary tissue is one of the best examples of the com-
plexity of the biological relationship between cellular prolif-
eration and cell death. The proliferation and apoptotic rates
in the mammary gland vary numerous times throughout life
depending on age, phase of the menstrual cycle, parity,
puerperal involution, and menopause. To study the dual
effect of proliferation and apoptosis in mammary epithelial
cells, we use the CRI (calculated as PI/AI). We find that,
although both proliferation and apoptosis occur throughout
the menstrual cycle, the maximal CRI values occur at about
the 28th day of the cycle. It is important to note that the iso-
lated comparison of the apoptotic and proliferation indices
has some limitations, because each index reflects both the
number of times that each event takes place in unit time and
the proportion of cells in the population capable of under-
going each event [48]. The CRI allows us to measure the
frequency of occurrence of proliferation relative to apopto-
sis. This serves to reduce or eliminate the effects of differ-
ences between samples; cells that do not undergo cellular
proliferation or apoptosis do not contribute to the calcula-
tion of the CRI [48].
In the present study we find that progesterone levels, irre-
spective of the stage of the menstrual cycle, are positively
correlated with the PI, as seen in animal models [49]. How-
ever, the AI decreases with progesterone levels of more
than 15 ng/ml, suggesting that mammary epithelial apopto-
sis is probably dependent on more than just alterations in
progesterone levels.
Aside from hormonal fluctuations, there are several factors
that change during the menstrual cycle. For example, sev-
eral Bcl-2 family (apoptosis-regulating) proteins are
expressed in the normal mammary epithelium, including the
anti-apoptotic proteins Bcl-2, Bcl-X, and MIC-1, and the
pro-apoptotic Bax. It has been shown that the relative ratios
of these various pro-apoptotic and anti-apoptotic members
of the Bcl-2 family determine the ultimate sensitivity or
resistance of cells to diverse apoptotic stimuli [46]. Ferri-
eres and colleagues [50] found a correlation between Bcl-
2 expression and progesterone levels, with greater Bcl-2
expression in the follicular phase, diminishing as the men-
strual cycle progresses. In contrast, Sabourin and col-
leagues [51] found that Bcl-2 was expressed preferentially
in lobular epithelial cells, with maximal expression at the
mid-cycle period and a sharp decrease at the end of the
menstrual cycle. Despite the different patterns of Bcl-2
expression in the first part of the menstrual cycle, the
results from those two studies suggest that the regulation
of Bcl-2 expression in breast tissue is hormone-dependent.
Furthermore, as discussed by Ferrieres and colleagues
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progesterone in diseases originating from epithelial lobular
components.
Another protein that is also under hormonal control and
undergoes cyclic variations throughout the menstrual cycle
is epidermal growth factor receptor (EGFR). EGFR is
involved in controlling proliferation and, probably, the differ-
entiation of normal breast epithelial cells. Gompel and col-
leagues [52] have shown that EGFR expression in
mammary epithelial cells is stronger in the luteal phase than
in the follicular phase. This suggests an effect of progestins
similar to that observed in breast cancer cell lines, although
it is unclear whether high EGFR levels correlate with higher
proliferation or with tissue differentiation.
Conclusion
Our data indicate that the numbers of proliferative and
apoptotic events vary during the menstrual cycle. The fre-
quency with which these events occur is also subject to
cyclical variations. The PI and the CRI are significantly
higher in the luteal phase. The PI and the AI culminate on
about the 24th day of the menstrual cycle, whereas the CRI
peaks on the 28th day. Elucidating the cyclical effects of
gonadal steroids on breast homeostasis is crucial if we are
to understand how alterations in breast structure and func-
tion during the menstrual cycle can lead to breast cancer
development.
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